Effect of piperacillin sodium and sulbactam sodium on respiratory function in patients with acute respiratory distress syndrome

Abstract

Purpose: To investigate the effect of the combination of piperacillin sodium and sulbactam sodium on respiratory function in patients with acute respiratory distress syndrome (ARDS).
 Methods: The clinical data for 151 ARDS patients admitted in Tianjin Hospital of ITCWM Nankai Hospital, Tianjin China from January 2020 to January 2021 were analyzed in this retrospective study. The patients were assigned to two groups based on different treatment regimens. Control group (COG) comprised 77 patients who received basic treatment (mechanical ventilation and drug treatment using oxazolidinones), while 74 patients who received basic treatment together with a combination of piperacillin sodium and sulbactam sodium (4 g of piperacillin and 0.5 g of sulbactam (for adults) through intravenous injection for 2 weeks continuously) were in study group (STG). Respiratory function was assessed in the two groups post-treatment using the basic dyspnea index (BDI) measurement. Mechanical ventilation time, intensive care unit (ICU) stay time and 28-day mortality rate after treatment, were also recorded.
 Results: Following treatment, patients in STG had significantly higher levels of partial pressure of arterial oxygen (PaO2) and oxygenation index (PaO2/FiO2), significantly lower partial pressure of carbon dioxide (PaCO2), markedly lower levels of pentraxin-3 (PTX-3) and procalcitonin (PCT), significantly higher score on BDI scale, and overtly lower mechanical ventilation time and ICU stay time, than COG (p < 0.05).
 Conclusion: Piperacillin sodium and sulbactam sodium combination significantly relieves clinical symptoms of ARDS such as breathlessness and chest discomfort in patients, resulting in improved respiratory function. The effectiveness of this combination makes it a potential first-line treatment for further large-scale investigation in ARDS management.